@HenrychihangFu1 @MorieGertz @CyclingDoctor One consideration in the standard risk subset analysis of CASTOR https://t.co/rg6DAWbSPH is that prior lenalidomide exposure was only 42%.
1,243 followers
286 followers
RT @victorshiyulin: Great news for #myeloma patients. In CASTOR trial, daratumumab+bortezomib/dexamethasone (D-Vd) led to longer PFS than V…
270 followers
Great news for #myeloma patients. In CASTOR trial, daratumumab+bortezomib/dexamethasone (D-Vd) led to longer PFS than Vd alone in R/R MM, with recent subgroup analysis reinforcing its efficacy regardless of cytogenetic risk status: https://t.co/VMYohn3zMQ
792 followers
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR ... https://t.co/gmvfeNfWyt